These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 21855532

  • 41. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
    Trtková K, Pašková L, Matiješčuková N, Kolář Z.
    Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
    [Abstract] [Full Text] [Related]

  • 42. Correlation between the expression of DNMT1, and GSTP1 and APC, and the methylation status of GSTP1 and APC in association with their clinical significance in prostate cancer.
    Zhang W, Jiao H, Zhang X, Zhao R, Wang F, He W, Zong H, Fan Q, Wang L.
    Mol Med Rep; 2015 Jul; 12(1):141-6. PubMed ID: 25738352
    [Abstract] [Full Text] [Related]

  • 43. A quantitative promoter methylation profile of prostate cancer.
    Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D.
    Clin Cancer Res; 2004 Dec 15; 10(24):8472-8. PubMed ID: 15623627
    [Abstract] [Full Text] [Related]

  • 44. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
    Li LC, Carroll PR, Dahiya R.
    J Natl Cancer Inst; 2005 Jan 19; 97(2):103-15. PubMed ID: 15657340
    [Abstract] [Full Text] [Related]

  • 45. Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells.
    Pandey M, Shukla S, Gupta S.
    Int J Cancer; 2010 Jun 01; 126(11):2520-33. PubMed ID: 19856314
    [Abstract] [Full Text] [Related]

  • 46. Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer.
    Suh CI, Shanafelt T, May DJ, Shroyer KR, Bobak JB, Crawford ED, Miller GJ, Markham N, Glode LM.
    Mol Cell Probes; 2000 Aug 01; 14(4):211-7. PubMed ID: 10970725
    [Abstract] [Full Text] [Related]

  • 47. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells.
    Lin X, Nelson WG.
    Cancer Res; 2003 Jan 15; 63(2):498-504. PubMed ID: 12543808
    [Abstract] [Full Text] [Related]

  • 48. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.
    Chuang CK, Chu DC, Tzou RD, Liou SI, Chia JH, Sun CF.
    Cancer Detect Prev; 2007 Jan 15; 31(1):59-63. PubMed ID: 17291695
    [Abstract] [Full Text] [Related]

  • 49. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
    Thelen P, Schweyer S, Hemmerlein B, Wuttke W, Seseke F, Ringert RH.
    Int J Oncol; 2004 Jan 15; 24(1):25-31. PubMed ID: 14654937
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.
    Li X, Kaplun A, Lonardo F, Heath E, Sarkar FH, Irish J, Sakr W, Sheng S.
    Mol Cancer Res; 2011 Jun 15; 9(6):733-45. PubMed ID: 21622623
    [Abstract] [Full Text] [Related]

  • 52. IFI16 in human prostate cancer.
    Alimirah F, Chen J, Davis FJ, Choubey D.
    Mol Cancer Res; 2007 Mar 15; 5(3):251-9. PubMed ID: 17339605
    [Abstract] [Full Text] [Related]

  • 53. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter.
    Wu LP, Wang X, Li L, Zhao Y, Lu S, Yu Y, Zhou W, Liu X, Yang J, Zheng Z, Zhang H, Feng J, Yang Y, Wang H, Zhu WG.
    Mol Cell Biol; 2008 May 15; 28(10):3219-35. PubMed ID: 18332107
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells.
    Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T.
    PLoS One; 2011 May 15; 6(9):e25634. PubMed ID: 21980513
    [Abstract] [Full Text] [Related]

  • 56. piR-31470 epigenetically suppresses the expression of glutathione S-transferase pi 1 in prostate cancer via DNA methylation.
    Zhang L, Meng X, Pan C, Qu F, Gan W, Xiang Z, Han X, Li D.
    Cell Signal; 2020 Mar 15; 67():109501. PubMed ID: 31837464
    [Abstract] [Full Text] [Related]

  • 57. Silencing of GSTP1, a prostate cancer prognostic gene, by the estrogen receptor-β and endothelial nitric oxide synthase complex.
    Re A, Aiello A, Nanni S, Grasselli A, Benvenuti V, Pantisano V, Strigari L, Colussi C, Ciccone S, Mazzetti AP, Pierconti F, Pinto F, Bassi P, Gallucci M, Sentinelli S, Trimarchi F, Bacchetti S, Pontecorvi A, Lo Bello M, Farsetti A.
    Mol Endocrinol; 2011 Dec 15; 25(12):2003-16. PubMed ID: 22052999
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. The epigenetic promise for prostate cancer diagnosis.
    Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W.
    Prostate; 2012 Aug 01; 72(11):1248-61. PubMed ID: 22161815
    [Abstract] [Full Text] [Related]

  • 60. Prostate cancer molecular detection in plasma samples by glutathione S-transferase P1 (GSTP1) methylation analysis.
    Dumache R, Puiu M, Motoc M, Vernic C, Dumitrascu V.
    Clin Lab; 2014 Aug 01; 60(5):847-52. PubMed ID: 24839830
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.